These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1069 related articles for article (PubMed ID: 26067088)

  • 41. FDG Avidity and Tumor Burden: Survival Outcomes for Patients With Recurrent Breast Cancer.
    Taghipour M; Wray R; Sheikhbahaei S; Wright JL; Subramaniam RM
    AJR Am J Roentgenol; 2016 Apr; 206(4):846-55. PubMed ID: 27003053
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prediction of occult lymph node metastasis by metabolic parameters in patients with clinically N0 esophageal squamous cell carcinoma.
    Moon SH; Kim HS; Hyun SH; Choi YS; Zo JI; Shim YM; Lee KH; Kim BT; Choi JY
    J Nucl Med; 2014 May; 55(5):743-8. PubMed ID: 24700884
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Metabolic tumor volume and total lesion glycolysis predict tumor progression and survival after salvage surgery for recurrent oral cavity squamous cell carcinoma.
    Choi WR; Oh JS; Roh JL; Kim JS; Oh I; Choi SH; Nam SY; Kim SY
    Head Neck; 2019 Jun; 41(6):1846-1853. PubMed ID: 30675738
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prognostic significance of novel ¹⁸F-FDG PET/CT defined tumour variables in patients with oesophageal cancer.
    Foley KG; Fielding P; Lewis WG; Karran A; Chan D; Blake P; Roberts SA
    Eur J Radiol; 2014 Jul; 83(7):1069-1073. PubMed ID: 24794862
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The prognostic value of total lesion glycolysis via 18F-fluorodeoxyglucose PET-CT in surgically treated esophageal squamous cell carcinoma.
    Park SY; Lee SJ; Yoon JK
    Ann Nucl Med; 2016 Jan; 30(1):81-8. PubMed ID: 26497543
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Artificial intelligence-based, volumetric assessment of the bone marrow metabolic activity in [
    Sachpekidis C; Enqvist O; Ulén J; Kopp-Schneider A; Pan L; Mai EK; Hajiyianni M; Merz M; Raab MS; Jauch A; Goldschmidt H; Edenbrandt L; Dimitrakopoulou-Strauss A
    Eur J Nucl Med Mol Imaging; 2024 Jul; 51(8):2293-2307. PubMed ID: 38456971
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Texture analysis of
    Nakajo M; Jinguji M; Nakabeppu Y; Nakajo M; Higashi R; Fukukura Y; Sasaki K; Uchikado Y; Natsugoe S; Yoshiura T
    Eur J Nucl Med Mol Imaging; 2017 Feb; 44(2):206-214. PubMed ID: 27613542
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prognostic significance of volume-based 18F-FDG PET/CT parameter in patients with surgically resected non-small cell lung cancer. Comparison with immunohistochemical biomarkers.
    Lee JY; Choi JY; Heo JH; Han J; Jang SJ; Kim K; Kim J; Shim YM; Kim BT
    Nuklearmedizin; 2016; 55(1):7-14. PubMed ID: 26875430
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pre-treatment metabolic tumor volume and total lesion glycolysis are useful prognostic factors for esophageal squamous cell cancer patients.
    Li YM; Lin Q; Zhao L; Wang LC; Sun L; Dai MM; Luo ZM; Zheng H; Wu H
    Asian Pac J Cancer Prev; 2014; 15(3):1369-73. PubMed ID: 24606467
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Volume-based quantitative FDG PET/CT metrics and their association with optimal debulking and progression-free survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery.
    Vargas HA; Burger IA; Goldman DA; Miccò M; Sosa RE; Weber W; Chi DS; Hricak H; Sala E
    Eur Radiol; 2015 Nov; 25(11):3348-53. PubMed ID: 25916387
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prognostic Value of Pretreatment Metabolic PET Parameters in Cervical Cancer Patients With Metabolic Complete Response After Concurrent Chemoradiotherapy.
    Son SH; Jeong SY; Chong GO; Lee YH; Park SH; Lee CH; Hong CM; Jeong JH; Lee SW; Ahn BC; Lee J
    Clin Nucl Med; 2018 Sep; 43(9):e296-e303. PubMed ID: 30036243
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Metabolic tumour burden assessed by ¹⁸F-FDG PET/CT associated with serum CA19-9 predicts pancreatic cancer outcome after resection.
    Xu HX; Chen T; Wang WQ; Wu CT; Liu C; Long J; Xu J; Zhang YJ; Chen RH; Liu L; Yu XJ
    Eur J Nucl Med Mol Imaging; 2014 Jun; 41(6):1093-102. PubMed ID: 24522797
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prognostic Value of Total Lesion Glycolysis Measured by 18F-FDG-PET/CT in Patients with Colorectal Cancer.
    Ogawa S; Itabashi M; Kondo C; Momose M; Sakai S; Kameoka S
    Anticancer Res; 2015 Jun; 35(6):3495-500. PubMed ID: 26026116
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Total Lesion Glycolysis Using ¹⁸F-FDG PET/CT as a Prognostic Factor for Locally Advanced Esophageal Cancer.
    Hong JH; Kim HH; Han EJ; Byun JH; Jang HS; Choi EK; Kang JH; Yoo IeR
    J Korean Med Sci; 2016 Jan; 31(1):39-46. PubMed ID: 26770036
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prognostic value of volumetric PET parameters in unresectable and metastatic esophageal cancer.
    Tamandl D; Ta J; Schmid R; Preusser M; Paireder M; Schoppmann SF; Haug A; Ba-Ssalamah A
    Eur J Radiol; 2016 Mar; 85(3):540-5. PubMed ID: 26860665
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pretreatment (18)F-FDG uptake heterogeneity can predict survival in patients with locally advanced nasopharyngeal carcinoma--a retrospective study.
    Yang Z; Shi Q; Zhang Y; Pan H; Yao Z; Hu S; Shi W; Zhu B; Zhang Y; Hu C
    Radiat Oncol; 2015 Jan; 10():4. PubMed ID: 25566697
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prognostic Value of Metabolic Tumor Volume and Total Lesion Glycolysis on Preoperative 18F-FDG PET/CT in Patients With Very Early and Early Hepatocellular Carcinoma.
    Hwang SH; Lee JW; Cho HJ; Kim KS; Choi GH; Yun M
    Clin Nucl Med; 2017 Jan; 42(1):34-39. PubMed ID: 27775949
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Can adaptive threshold-based metabolic tumor volume (MTV) and lean body mass corrected standard uptake value (SUL) predict prognosis in head and neck cancer patients treated with definitive radiotherapy/chemoradiotherapy?
    Akagunduz OO; Savas R; Yalman D; Kocacelebi K; Esassolak M
    Nucl Med Biol; 2015 Nov; 42(11):899-904. PubMed ID: 26275933
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prognostic value of pretreatment 18F-fluorodeoxyglucose positron emission tomography/CT volume-based parameters in patients with oropharyngeal squamous cell carcinoma with known p16 and p53 status.
    Kikuchi M; Koyasu S; Shinohara S; Usami Y; Imai Y; Hino M; Itoh K; Tona R; Kanazawa Y; Kishimoto I; Harada H; Naito Y
    Head Neck; 2015 Oct; 37(10):1524-31. PubMed ID: 24890445
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The role of metabolic tumor volume and total lesion glycolysis on ¹⁸F-FDG PET/CT in the prognosis of epithelial ovarian cancer.
    Lee JW; Cho A; Lee JH; Yun M; Lee JD; Kim YT; Kang WJ
    Eur J Nucl Med Mol Imaging; 2014 Oct; 41(10):1898-906. PubMed ID: 24852188
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 54.